-
AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer
Researchers promises that AMG 509 provides a targeted immunotherapy approach to engage a patient’s T…
Researchers promises that AMG 509 provides a targeted immunotherapy approach to engage a patient’s T…